Why Protagonist Therapeutics, Inc. (PTGX) stock moved
Protagonist Therapeutics, Inc. (PTGX) shares fell 4.4% to $138.70 as of September 24, 2026, a moderate decline from the prior close of $145.07. BestStocks flagged the session as a major change for PTGX. The move is tied to price move down. Below, we break down what changed for PTGX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
PTGX fell 4.4% to $138.70
PTGX fell 4.4% in its latest session, moving from $145.07 to $138.70.
What it means for Protagonist Therapeutics, Inc. investors
For Protagonist Therapeutics, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Protagonist Therapeutics, Inc. (PTGX) moved +3.01% from $134.27 to $138.31 on 2026-07-21; Protagonist Therapeutics, Inc. (PTGX) moved +6.82% from $132.02 to $141.03 on 2026-07-17, reaching a new 30-day high. Weighing against that: Material negative event; Negative session, down 4.4%. Wall Street's consensus price target sits at $176.29, implying +27.1% upside from $138.70. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (53/100). With earnings roughly 42 days out, the next report is the most likely near-term test of the move.
PTGX price reaction
PTGX last traded at $138.70, down $6.37 (-4.39%) from the previous close of $145.07. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $138.70 and $154.72, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Protagonist Therapeutics, Inc. (PTGX)
The consensus analyst price target on Protagonist Therapeutics, Inc. (PTGX) is $176.29, 27.1% above the recent $138.70. Over the past 90 days analysts logged 1 upgrade, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on PTGX line up.
The bullish case
- Wall Street's consensus price target of $176.29 implies +27.1% upside from $138.70.
- The Street's most bullish target is $190.00 (+37.0%).
- 1 analyst upgrade in the past 90 days, most recently Goldman Sachs to Buy (2026-08-10).
- Protagonist Therapeutics, Inc. (PTGX) moved +3.01% from $134.27 to $138.31 on 2026-07-21.
- Positive price momentum.
The bearish case
- Material negative event.
- Negative session, down 4.4%.
- Protagonist Therapeutics, Inc. (PTGX) moved -2.88% from $139.45 to $135.44 on 2026-07-22.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 23, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PTGX
Frequently asked questions about PTGX
Why did Protagonist Therapeutics, Inc. (PTGX) stock move?
PTGX fell 4.4% to $138.70. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did PTGX stock fall?
PTGX lost 4.39% ($6.37) versus the prior close of $145.07, last trading at $138.70 on 0.8× average volume.
When is Protagonist Therapeutics, Inc.'s next earnings date?
PTGX's next earnings report is estimated for 2026-11-05 — about 42 days away.
What is the analyst price target for PTGX?
The consensus analyst price target for PTGX is $176.29, about 27.1% above the current $138.70. Over the past 90 days, analysts recorded 1 upgrade, 11 maintains, and 0 downgrades.
How BestStocks tracks PTGX
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for PTGX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 24, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.